DURHAM, N.C., May 31, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Mike Sherman, Chief Executive Officer, will participate in a fireside chat at the upcoming Jefferies Healthcare Conference on Wednesday, June 7, 2023, at 3:30 p.m. in New York City.
A live audio webcast of the presentation will be available on the Investor Relations section of Chimerix’s website at ir.chimerix.com, where it will be archived for approximately 90 days.
About Chimerix
Chimerix is a biopharmaceutical company with a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The Company’s most advanced clinical-stage development program, ONC201, is in development for H3 K27M-mutant glioma, a form of high-grade glioma which often includes GBM and DIPG subsets.
CONTACTS:
Michelle LaSpaluto
919 972-7115
This email address is being protected from spambots. You need JavaScript enabled to view it.
Will O’Connor
Stern Investor Relations
212-362-1200
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$2.99 |
Daily Change: | 0.14 4.91 |
Daily Volume: | 2,451,195 |
Market Cap: | US$268.920M |
December 09, 2024 November 11, 2024 November 07, 2024 August 13, 2024 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB